

Resource Summary Report

Generated by ASWG on Aug 9, 2026

APC/Cyanine7 anti-human CD8

RRID:AB_2044006

Type: Antibody

Proper Citation

BioLegend Cat# 344714, RRID:AB_2044006

Antibody Information

URL: http://antibodyregistry.org/AB_2044006

Proper Citation: BioLegend Cat# 344714, RRID:AB_2044006

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Cyanine7 anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2044006

Vendor: BioLegend

Catalog Number: 344714

Alternative Catalog Numbers: 344713

Record Creation Time: 20250820T003005+0000

Record Last Update: 20250820T082610+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community. Contact(s): [Jing Chen](#), [Mark Atkinson](#), [Todd Brusko](#), [Clayton Mathews](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for APC/Cyanine7 anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 52 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zhang Y, et al. (2026) Human receptive endometrial assembloid for deciphering the implantation window. eLife, 12.

Sajani A, et al. (2026) Heterogeneity and plasticity of the naive CD4+ T cell compartment. Cell reports, 45(3), 116980.

Li YR, et al. (2026) Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. STAR protocols, 7(1), 104340.

Ruan Z, et al. (2026) Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy. Med (New York, N.Y.), 7(4), 101026.

Fan AE, et al. (2025) STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition. Molecular cancer therapeutics, 24(3), 419.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Lyu Z, et al. (2025) Protocol for assessing pharmacokinetics and pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging. STAR protocols, 6(3), 103957.

Schiantarelli J, et al. (2025) Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer cell, 43(2), 308.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. Frontiers in immunology, 16, 1609658.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. Cell, 188(14), 3823.

Thomé J, et al. (2025) C-reactive protein induced T cell activation is an indirect monocyte-dependent mechanism involving the CD80/CD28 pathway. *Frontiers in immunology*, 16, 1622865.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. *Med (New York, N.Y.)*, 100804.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. *Cell reports. Medicine*, 6(10), 102400.

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. *Cell reports. Medicine*, 6(12), 102466.

Sureshchandra S, et al. (2025) Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils. *Immunity*, 58(12), 3130.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. *STAR protocols*, 6(2), 103810.

Semitekolou M, et al. (2025) Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer. *iScience*, 28(9), 112804.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.